Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2023 09:00 ET | Source: GeoVax, Inc.

GeoVax to Participate in Upcoming December Investor Events

ATLANTA, GA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
October 24, 2023 09:00 ET | Source: GeoVax, Inc.

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

ATLANTA, GA, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
May 09, 2023 09:00 ET | Source: GeoVax, Inc.

GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference

ATLANTA, GA, May 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
April 26, 2023 09:00 ET | Source: GeoVax, Inc.

GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host

ATLANTA, GA, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers and infectious...
March 15, 2023 09:00 ET | Source: GeoVax, Inc.

GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress

Dr. Diamond and City of Hope COVID-19 Vaccine Team Nominated forBest Academic/Research Team Award ATLANTA, GA, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq:...
February 15, 2023 09:00 ET | Source: GeoVax, Inc.

GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial

Mobile Community Clinical Research Facility to be Deployed in California ATLANTA, GA, Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
February 08, 2023 09:00 ET | Source: GeoVax, Inc.

GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines

Focused on Providing Rapid Response to Combat Emerging Infectious Threats ATLANTA, GA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
February 07, 2023 09:00 ET | Source: GeoVax, Inc.

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

Phase 1/2 Trial Now Active at Stanford, Emory, and Thomas Jefferson Universities ATLANTA, GA, Feb. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
January 04, 2023 09:00 ET | Source: GeoVax, Inc.

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023

ATLANTA, GA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
September 07, 2022 09:00 ET | Source: GeoVax, Inc.

GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine (GEO-CM04S1) and Phase 1/2 Clinical Trial for Advanced Head and Neck Cancer (Gedeptin®) ATLANTA, GA, Sept. 07, 2022 (GLOBE...

Next Page keyboard_arrow_right